Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Investor Presentation just updated

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Nov 17, 2022 7:10pm

231 Views

Post# 35108916

RE:RE:Investor Presentation just updated

What % cost of a combination treatment do you calculate Pela to be Noteable.?

It is that figure, that ultimately will value ONCY, not fantasy buyout numbers. I just wondered if you'd even considered this and have ever shared such an opinion on this BB.

Let's face it, getting a product approved is great, but if it only brings in peanuts then what is the company worth. THIS is going to become important, assumng a Phase III ever gets going before the patent's expire.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas